-

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

Industry:

Personalis, Inc.

NASDAQ:PSNL
Release Versions
English

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

More News From Personalis, Inc.

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in...

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance...

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company’s NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California. A focus of this year’s data is the introduction of a new NeXT Personal MRD test option...
Back to Newsroom